231
Participants
Start Date
May 5, 2022
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2039
P-BCMA-ALLO1 CAR-T cells
Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy
Rimiducid
Safety switch activator
RECRUITING
Roswell Park Comprehensive Cancer Center, Buffalo
RECRUITING
University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
RECRUITING
Emory University, Atlanta
RECRUITING
Blood Marrow and Transplant Group of Georgia, Atlanta
RECRUITING
Vanderbilt University Medical Center, Nashville
RECRUITING
Cleveland Clinic, Cleveland
RECRUITING
University of Cincinnati, Cincinnati
RECRUITING
Wayne State - Karmanos Cancer Institute, Detroit
RECRUITING
University of Iowa, Iowa City
RECRUITING
City of Hope, Chicago
TERMINATED
Advocate Aurora Health, Park Ridge
RECRUITING
University of Kansas Medical Center, Kansas City
ACTIVE_NOT_RECRUITING
University of Oklahoma, Health Sciences Center, Oklahoma City
RECRUITING
Houston Methodist Research Institute, Houston
RECRUITING
Sarah Cannon Research Institute - Methodist Healthcare, San Antonio
RECRUITING
Sarah Cannon Research Institute - St. David's South Austin Medical Center, Austin
RECRUITING
City of Hope, Goodyear
RECRUITING
University of California San Diego, San Diego
TERMINATED
University of California San Francisco, San Francisco
NOT_YET_RECRUITING
University of North Carolina at Chapel Hill, Chapel Hill
RECRUITING
University of Pennsylvania, Philadelphia
Lead Sponsor
Roche-Genentech
INDUSTRY
Poseida Therapeutics, Inc.
INDUSTRY